Evidence map›Paper›PMID 30693992›Full record

ArticleBioFactors (Oxford, England)2019

Human T lymphotropic virus type 1 and risk of cardiovascular disease: High-density lipoprotein dysfunction versus serum HDL-C concentrations.

Sara Samadi, Samaneh Abolbashari, Zahra Meshkat, Amir Hooshang Mohammadpour, Theodoros Kelesidis, Aida Gholoobi, Mehrane Mehramiz, Mahla Tabadkani, Fatemeh Sadabadi, Razieh Dalirfardouei and 3 more

Open access · greenAbstract read
In one paragraph

Article in BioFactors (Oxford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Reduced antioxidant high-density lipoprotein function in heart failure with preserved ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2026
    Observational
  3. Review
  4. Article
  5. Cholesterol, lipoproteins, and COVID-19: Basic concepts and clinical applications.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Sara SamadiDepartment of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Samaneh AbolbashariDepartment of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Zahra MeshkatDepartment of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir Hooshang MohammadpourPharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran.
Theodoros KelesidisDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Aida GholoobiDepartment of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mehrane MehramizDepartment of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mahla TabadkaniMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Fatemeh SadabadiDepartment of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Razieh DalirfardoueiDepartment of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon A FernsBrighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex, UK.
Majid Ghayour-MobarhanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0002-1081-6754
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0002-4968-0962
Mashhad University of Medical Sciences · IRBrighton and Sussex Medical School · GBUniversity of California, Los Angeles · US

Funding

Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIVR01AG059502 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI KELESIDIS, THEODOROS · 2018 to 2022
$2.0M
Oxidized HDL in the intersection of HIV, immune activation and atherosclerosisK08AI108272 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2013 to 2017
$915k
Elucidating the impact of molecular signatures of immune senescence on aging in chronic treated HIVR03AG059462 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2018 to 2019
$156k
Mashhad University of Medical Sciences 941684NIAID NIH HHS K08 AI108272NIA NIH HHS R01 AG059502NIA NIH HHS R03 AG059462
6 · The paper itself

Abstract

High-density lipoprotein (HDL) is thought to be protective against cardiovascular disease (CVD), and HDL dysfunction is considered to be a risk factor for CVD. It is unclear whether there is an association between Human T lymphotropic virus type 1 (HTLV1) infection and CVD risk. We have assessed HDL lipid peroxidation (HDLox) as a marker of HDL dysfunction and CVD risk in a subgroup of the MASHAD cohort study. One hundred and sixty two individuals including 50 subjects positive for HTLV1 infection and 112 individuals negative for HTLV1 infection were recruited. Anthropometric and biochemical parameters including serum hs-CRP, fasted lipid profile (HDL-C, LDL, triglycerides, and cholesterol), and fasting blood glucose were determined. Serum HDLox was also measured in the study participants. Multivariate analyses were used to evaluate the association between serum HDLox and HTLV1 infection. None of the traditional CVD risk factors were associated with HTLV1 infection, including serum HDL-C. However, serum HDLox was independently associated with the presence of HTLV1 infection. Logistic regression analysis showed that subjects who were positive for HTLV1 infection were also significantly more likely than uninfected individuals to have higher HDLox (odds ratio 9.35, 95%CI: 3.5-24.7; P < 0.001). HDLox was increased approximately 20% (P < 0.001) in infected subjects compared to the uninfected group. Serum HDLox is a marker of CVD risk factor and increased in individuals affected by HTLV1 infection compared to healthy subjects. © 2019 BioFactors, 45(3):374-380, 2019.

Indexed as

AdultBiomarkersCardiovascular DiseasesCholesterol, HDLFemaleHumansHuman T-lymphotropic virus 1Lipoproteins, HDLMaleMiddle AgedRisk FactorsSoftwareTriglyceridesBiomarkersCholesterol, HDLLipoproteins, HDLTriglyceridesHDL lipid peroxidationHDLoxhigh-density lipoproteinHTLV1 infectionviral infectious disease

Identifiers

PMID30693992
PMCPMC6548577
OpenAlexW2914064338

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.